Tribunal rules R&D expenses not deductible for Baddi unit under section 80IC &Dexpenses

The Tribunal upheld the CIT(A)'s decision, ruling that R&D expenses from Mahape and Sinnar units should not be allocated to the Baddi unit for deduction under section 80IC. The Tribunal found no direct nexus between the R&D activities and the Baddi unit's manufacturing, supported by the AO's remand report. The decision aligned with principles from Zandu Pharmaceuticals and Bush Boake Allen cases, emphasizing the need for a direct connection for expense allocations. The Revenue's appeal was dismissed.

---

---

Issues Involved:
1. Admission of additional evidence by CIT(A) without assigning reasons.
2. Apportionment of R&D expenses to Baddi unit for computing deduction under section 80IC.
3. Reliance on the decision of the Hon'ble jurisdictional High Court in the Zandu Pharmaceuticals Works Ltd. case.

Issue-wise Detailed Analysis:

1. Admission of Additional Evidence by CIT(A):
The Revenue contended that the CIT(A) erred by admitting additional evidence during appellate proceedings without providing reasons or addressing the objections raised by the AO in his remand report. However, the CIT(A) clarified that the AO had examined all additional evidence during the remand proceedings and did not find any direct nexus between the R&D expenses incurred at Mahape and Sinnar units and the products manufactured at the Baddi unit. Thus, the CIT(A) concluded that the additional evidence was properly considered.

2. Apportionment of R&D Expenses to Baddi Unit:
The primary issue was whether R&D expenses incurred at Mahape and Sinnar units should be allocated to the Baddi unit for computing the deduction under section 80IC of the Income-tax Act, 1961. The Tribunal had previously remanded the case to the AO to determine if there was a direct nexus between the R&D expenses and the Baddi unit. The AO, in his remand report, confirmed that the R&D activities at Mahape and Sinnar had no connection with the products manufactured at Baddi. The CIT(A) relied on this report and the comprehensive list of products manufactured at Baddi, which showed no overlap with the R&D activities at the other units. Additionally, the CIT(A) highlighted that similar allocations of R&D expenses in subsequent assessment years (2010-11 and 2013-14) were deleted by CIT(A), reinforcing the decision not to allocate these expenses to Baddi.

3. Reliance on Zandu Pharmaceuticals Works Ltd. Case:
The Revenue argued that the CIT(A) erroneously relied on the Zandu Pharmaceuticals Works Ltd. decision, where each unit had a separate R&D unit, unlike the assessee's case where R&D was centralized. The CIT(A) and the Tribunal, however, found that the principles from the Zandu case applied here as well. The Zandu case established that R&D expenses should not be apportioned to units unless there is a direct nexus between the R&D activities and the unit's manufacturing activities. The CIT(A) found no such nexus in this case, as the R&D at Mahape and Sinnar did not benefit the Baddi unit's products. This was further supported by the Madras High Court's decision in Bush Boake Allen (India) Ltd. vs. ACIT, which emphasized the necessity of a direct connection for such allocations.

Conclusion:
The Tribunal upheld the CIT(A)'s decision, affirming that no R&D expenses incurred at Mahape and Sinnar units should be allocated to the Baddi unit for computing the deduction under section 80IC. The Tribunal found that the CIT(A) had correctly applied the principles from the Zandu Pharmaceuticals and Bush Boake Allen cases and that the AO's remand report supported the absence of any direct nexus between the R&D activities and the Baddi unit's manufacturing. Thus, the appeal filed by the Revenue was dismissed.

---